Supplementary Table 1. ACCORD Variables Available for Risk Prediction Model. **Bolded** candidate variables had <10% missing data and were considered in risk prediction models.

Variable Domain	Individual Variables
Demographic/Anthropometric	Age, sex, race, body mass index, systolic blood pressure,
	diastolic blood pressure, heart rate, randomized treatment arm,
	body mass index, waist circumference
Clinical/Medical History	Systolic blood pressure, diastolic blood pressure, heart rate,
	History of myocardial infarction, stroke, coronary artery bypass
	graft surgery, cardiovascular disease, percutaneous coronary
	intervention/atherectomy, albuminuria, low ankle-brachial
	index, current smoker, level of education, years of diabetes
	mellitus, hypertension, hyperlipidemia, family history of heart
	failure, hypoglycemic event requiring medical assistance,
	hypoglycemic event requiring any assistance, neuropathy ,
	vibration sensation loss, pressure sensation loss, Mini-Mental
	State Examination total score, Denver Developmental Screening
	Test total score, Stroop score, Rey Auditory Verbal Learning Test
	score, former cigarette smoker, lives with one or more people,
	foot ulcer requiring antibiotics, number of alcoholic drinks per
	week, Health Utilities Index Mark3 score, Health Utilities Index
	Mark2 score, physical health survey, mental health survey, diet
	summary score, total exercise expenditure calories/week, total moderate-intensive exercise expenditure calories/week, documented
	blood glucose <50mg/dl, serum creatinine doubling, right leg pre-
	tibial edema, left leg pre-tibial edema, amputation of lower
	extremity, photocoagulation, cataract extraction, severe vision loss,
	Michigan Neuropathy Screening Instrument score, visual acuity
	score R eye, visual acuity score L eye, depression, eye disease,
	full insurance benefits, partial insurance benefits, foot appearance ,
	ankle reflexes, neuropathy screening instrument score, feeling
	score, nutrition education
Laboratory	Potassium, serum creatinine, glycated hemoglobin, total
Laboratory	cholesterol, triglycerides, very low-density lipoprotein, low-
	density lipoprotein, HDL-C, fasting plasma glucose, alanine
	aminotransferase, creatine kinase, estimated glomerular
	filtration rate, urinary albumin, urinary creatinine
Baseline Medications	Loop diuretic, thiazide diuretic, potassium-sparing diuretic,
	angiotensin II receptor blocker, angiotensin-converting enzyme
	inhibitor, dihydropyridine calcium channel blockers, non-
	dihydropyridine calcium channel blockers, alpha-blockers,
	beta-blockers, vasodilators, reserpine, digitalis, anti-arrhythmic
	therapies, nitrates, sulfonylureas, biguanides, meglitinides,
	alpha-glucosidase inhibitors, NPH insulin, thiazolidinediones,
	regular insulin, Lispro/Aspart insulin, premixed insulin, bile-
	acid sequestrants, statins, fibrates, cholesterol absorption
	inhibitors, niacin, oral anticoagulants, nonsteroidal anti-
	inflammatory drugs, cyclooxygenase-2 inhibitors, aspirin,

	thyroid agent, progestins, estrogens, oral asthma drugs, any antidepressant, drugs for osteoporosis, vitamins, over-the-counter medication, herbal medication
Neuro Magnetic Resonance	Intracranial volume, basal ganglia normal, basal ganglia abnormal,
Imaging	gray mater normal, white matter normal, gray matter abnormal,
	white matter abnormal, brain volume normal, brain volume
	abnormal, gray matter total, white matter total
Electrocardiographic	ST-segment depression anterolateral, posterior, anterior, T-wave
	inversion, AV conduction defect, PR interval, QRS duration, QTc
	interval, QRS-axis, P-axis, T-axis, R-wave amplitude (lead
	aVL), S-wave amplitude (lead V3), left ventricular hypertrophy
	(Cornell Voltage), atrial fibrillation

Supplementary Table 2. Identified variables in each of the three variable selection methods: random survival forest (RSF), stepwise forward selection, and stepwise backwards selection.

Random Survival Forest (RSF)	Stepwise Forward Selection	Stepwise Backwards Selection	
Age	Age	Age	
T-wave axis*	T-wave axis*	T-wave axis*	
QTc duration*	Hemoglobin A1c*	Hemoglobin A1c*	
Diastolic blood pressure	Serum creatinine	Urine albumin	
Hemoglobin A1c*	Diastolic blood pressure	Serum creatinine	
Serum creatinine	QTc duration*	Serum potassium	
HDL-C	History of MI	QRS duration	
QRS duration	PR duration*	Fasting plasma glucose	
Body mass index	Urine creatinine	History of MI	
History of MI	HDL-C	History of CABG	
Fasting plasma glucose	Body mass index	PR duration*	
History of CABG	QRS duration	Urine creatinine	
Systolic blood pressure		HDL-C	
		Diastolic blood pressure	

^{*} Indicates the variable was removed from the relationship modeling step as the variable was not a routine clinical marker, clinically similar to other variables, or not available in the validation dataset.

Supplementary Table 3. Cox proportional hazard parameter estimates for the estimated 5-year risk of HF.

Variable	β-estimate	Hazard Ratio (95% Confidence Interval))	P-value
Age	0.039	1.04 (1.02-1.06)	< 0.001
Fasting plasma glucose	0.002	1.00 (1.00-1.01)	0.03
Body mass index	0.057	1.06 (1.04-1.08)	< 0.001
Systolic blood pressure	0.015	1.02 (1.01-1.02)	< 0.001
Diastolic blood pressure	-0.025	0.98 (0.96-0.99)	< 0.001
Serum creatinine	0.710	2.03 (1.31-3.16)	0.002
HDL-C	-0.023	0.98 (0.97-0.99)	< 0.001
QRS duration (≥120 msec)	0.583	1.79 (1.31-2.45)	< 0.001
History of MI	0.600	1.82 (1.37-2.41)	< 0.001
History of CABG	0.673	1.96 (1.46-2.64)	< 0.001


Baseline survival: 0.97358

SUPPLEMENTARY DATA **Supplementary Table 4.** Baseline characteristics for both the ACCORD and ALLHAT datasets.


	ACCORD	ALLHAT	Dl
	(n=8,756)	(n=10,819)	<i>P</i> -value
Female, %	3370 (38.5)	5306 (49.0)	< 0.01
Age (years), %	62.7 (6.6)	67.0 (7.3)	< 0.01
Race, %			< 0.01
Black	1622 (18.5)	4109 (38.0)	
Other	1645 (18.8)	580 (5.4)	
White	5489 (62.7)	6130 (56.7)	
Systolic blood pressure (mmHg), sd	136.4 (16.9)	144.7 (13.5)	< 0.01
Diastolic blood pressure (mmHg), sd	75.0 (10.5)	82.0 (9.9)	< 0.01
Body mass index (kg/m ²), sd	32.1 (5.4)	31.0 (6.0)	< 0.01
QRS duration (>120 ms), %	636 (7.3)	806 (7.4)	0.64
LV hypertrophy ¹ , %	332 (3.8)	983 (9.1)	< 0.01
Fasting plasma glucose (md/dL), sd	175.2 (55.9)	172.4 (74.5)	0.18
Potassium (md/dL), sd	4.5 (0.5)	4.4 (0.7)	0.39
Serum creatinine (md/dL), sd	0.9(0.2)	1.0 (0.3)	0.31
Estimated glomerular filtration rate (mL/min), sd	91.5 (27.3)	80.7 (21.4)	< 0.01
Total cholesterol (mg/dL), sd	183.6 (41.7)	215.4 (45.5)	< 0.01
Triglycerides (md/dL), sd	190.6	191.1	
riigiycerides (iiid/dL), sd	(149.8)	(153.0)	0.87
Low-density lipoprotein cholesterol (md/dL), sd	105.1 (33.9)	134.1 (38.8)	< 0.01
HDL-C (md/dL), sd	41.9 (11.5)	44.8 (12.4)	< 0.01
History of myocardial infarction, %	1237 (14.1)	2063 (19.1)	< 0.01
History of stroke, %	502 (5.7)	728 (6.7)	0.29
History of coronary artery bypass graft surgery, %	918 (10.5)	1141 (10.5)	0.91
Current cigarette smoker, %	1078 (12.3)	1342 (12.4)	0.86

¹Determined by Cornell Voltage criteria


Supplementary Figure 1. The analysis flow for developing and validating models.




Supplementary Figure 2. Calibration of the WATCH-DM risk score for the integer-based, Cox regression-based, and RSF-based models in the internally validated dataset (ACCORD). Predicted vs observed 5-year incidence of heart failure based on deciles of predicted risk. Calibration was acceptable (Hosmer-Lemeshow statistics p≥0.20 for all models).




Supplementary Figure 3. Calibration of the WATCH-DM risk score for the integer-based, Cox regression-based, and RSF-based models in the externally validated dataset (ALLHAT). Predicted vs observed 5-year incidence of heart failure based on deciles of predicted risk. Calibration was acceptable (Hosmer-Lemeshow statistics p≥0.10 for all models).



Supplementary Figure 4. Cumulative incidence of HF across quintiles of WATCH-DM: Q1 (\leq 7); Q2 (8-9); Q3 (10); Q4 (11-13); Q5 (\geq 14) in the validation dataset, ALLHAT.



Supplementary Figure 5. Kaplan-Meier curves for HF events by phenotype in the ALLHAT (external validation) cohort. The *p*-value was calculated using the *logrank* test.



Supplementary Figure 6. Cumulative incidence curves for incident HF in each of the 5 risk strata by HF phenotype in the external validation (ALLHAT) dataset.

